Form 4: Liquidia CEO Roger Jeffs Receives Equity Grants

Liquidia Corp's CEO and Director, Roger Jeffs, reported the acquisition of 115,344 Restricted Stock Units and 173,016 Performance Stock Units.

Summary

• Roger Jeffs, Chief Executive Officer and Director of Liquidia Corp (LQDA), reported the acquisition of equity securities.
• On January 16, 2026, Jeffs was granted 115,344 Restricted Stock Units (RSUs) at a price of $0, which convert into common stock on a one-for-one basis.
• The RSUs granted on January 16, 2026, will vest 25% on January 11, 2027, with the remaining 75% vesting at 6.25% every three months thereafter.
• Also on January 16, 2026, Jeffs was granted 173,016 Performance Stock Units (PSUs) at a price of $0, which convert into common stock on a one-for-one basis.
• The PSUs will vest 25% on January 11, 2027 (or the date the Issuer files its Form 10-K for fiscal year ending December 31, 2026, if later), with the remaining 75% vesting at 6.25% every three months, contingent upon achieving milestone-based vesting conditions related to net product sales revenue from YUTREPIA in 2026.
• Following these transactions, Jeffs directly beneficially owns 1,152,872 shares of Common Stock, which includes 72,375 unvested RSUs from a January 11, 2023 grant, 110,669 unvested RSUs from a January 11, 2024 grant, 171,995 unvested RSUs from a January 11, 2025 grant, the 115,344 unvested RSUs from the January 16, 2026 grant, and 10,696 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
• Jeffs indirectly beneficially owns 46,595 shares of Common Stock through the Roger A. Jeffs Living Trust UAD 2/29/2000, where he is the trustee.
• Jeffs also indirectly beneficially owns 1,541,667 shares of Common Stock through Serendipity BioPharma LLC, where he is a manager with sole voting and dispositive power.

Sentiment

Score: 6

Explanation: The filing reports routine executive equity grants, including performance-based units, which align management incentives with company performance. This is a neutral to slightly positive event as it reflects standard compensation practices and incentivizes future growth.

Positives

• The equity grants, particularly the Performance Stock Units (PSUs), align the Chief Executive Officer's incentives directly with the company's future performance, specifically YUTREPIA sales.
• The grants represent a commitment to long-term executive retention and motivation, which can be beneficial for sustained strategic execution.

Negatives

• The issuance of new equity awards, even if unvested, represents potential future dilution for existing shareholders when these units convert to common stock.

Risks

• The vesting of the 173,016 Performance Stock Units is contingent on achieving specific milestone-based conditions related to net product sales revenue from YUTREPIA in 2026, introducing a performance risk for the full realization of these awards.
• Future stock price volatility could impact the value of these equity grants for the reporting person and the potential dilution for shareholders.

Future Outlook

The future outlook for Roger Jeffs' compensation is tied to the vesting schedules of the RSUs and PSUs, extending into 2027 and beyond. The PSUs' full realization is contingent on Liquidia's performance, specifically YUTREPIA net product sales revenue in 2026, as disclosed in the FY2026 10-K.

Industry Context

The granting of Restricted Stock Units and Performance Stock Units is a common practice in the biotechnology and pharmaceutical industries for executive compensation. These equity awards are designed to incentivize long-term performance and align the interests of executives with those of shareholders, particularly in companies with significant product development and commercialization milestones like YUTREPIA.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and PSUs, is a standard component of executive pay packages across the biotech and pharmaceutical sectors, comparable to practices at companies like United Therapeutics or other pulmonary hypertension drug developers.
• The inclusion of performance-based vesting conditions, such as those tied to YUTREPIA net product sales, is a strong governance practice that links executive rewards directly to commercial success, a common feature in growth-oriented biopharma companies.

Related Party Transactions

• Roger Jeffs indirectly holds shares through the Roger A. Jeffs Living Trust UAD 2/29/2000, where he is the trustee.
• Roger Jeffs indirectly holds shares through Serendipity BioPharma LLC, where he is a manager and has sole voting and dispositive power.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting of RSUs and PSUs, but also benefit from aligned management incentives for company performance, particularly YUTREPIA sales.
• Employees: The filing details executive compensation, which can set a precedent or context for broader employee incentive programs.

Next Steps

• The vesting of 25% of the RSUs and PSUs is scheduled for January 11, 2027, or later for PSUs depending on the FY2026 10-K filing.
• Subsequent quarterly vesting of 6.25% for both RSUs and PSUs will occur following the initial vesting date.
• The company will need to disclose YUTREPIA net product sales revenue in its FY2026 10-K to determine the vesting of the performance-based PSUs.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for the CEO, which is a standard practice to align executive incentives with shareholder value. It does not present new information that would fundamentally alter the investment thesis for Liquidia Corp, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Liquidia Corp, LQDA, Roger Jeffs, SEC Form 4, Restricted Stock Units, Performance Stock Units, Equity Grant, Executive Compensation, Beneficial Ownership, YUTREPIA